共 50 条
Consensus statement on antimicrobial therapy of intra-abdominal infections in Asia
被引:26
|作者:
Hsueh, Po-Ren
Hawkey, Peter Michael
机构:
[1] Natl Taiwan Univ Hosp, Coll Med, Dept Lab Med, Div Clin Microbiol, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Coll Med, Dept Internal Med, Div Infect Dis, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Coll Med, Dept Internal Med, Div Clin Microbiol, Taipei, Taiwan
[4] Univ Birmingham, Sch Med, Birmingham, W Midlands, England
[5] Birmingham Heartlands & Solihull NHS Trusts, Hlth Protect Agcy, W Midlands Publ Hlth Lab, Birmingham, W Midlands, England
关键词:
intra-abdominal infections;
antimicrobial therapy;
Asia;
consensus;
SUSCEPTIBILITIES;
RESISTANCE;
AGENTS;
D O I:
10.1016/j.ijantimicag.2007.03.002
中图分类号:
R51 [传染病];
学科分类号:
100401 ;
摘要:
The selection of antimicrobial agents in the 2006 Guidelines (consensus statement) on Empiric Therapy for Complicated Intra-Abdominal Infections (IAIs) in Asia was based on resistance and epidemiological data from the Asian region. In these 2006 guidelines, single agent therapy using the beta-lactam/beta-lactamase inhibitors ampicillin/sulbactam or cefoperazone-sulbactam is recommended for mild-to-moderate cases, while piperacillin-tazobactam is recommended for high-severity cases. When using carbapenems, ertapenem is recommended for mild-to-moderate cases, while imipenem and meropenem are recommended for high-severity cases. For combination regimes, two types of agents are recommended: cephalosporin-based and monobactam-based. For mild-to-moderate cases, a third generation cephalosporin plus metronidazole is recommended. For high-severity cases, a third or fourth generation cephalosporin plus metronidazole +/- amikacin is recommended. For the monobactam-based regimen, aztreonam plus metronidazole is recommended for high-severity cases only. (c) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:129 / 133
页数:5
相关论文